1. Langer-Safer P, Levine M, Ward D. Immunological method for mapping genes on Drosophila polytene chromosomes. Proc Natl Acad Sci USA. 1982; 79:4381–4385.
2. Lichter P, Cremer T, Tang CJ, et al. Rapid detection of human chromosome 21 aberrations by in situ hybridization. Proc Natl Acad Sci USA. 1988; 85:9664–9668.
3. Pinkel D, Landegent J, Collins C, et al. Fluorescent in situ hybridization with human chromosome-specific libraries: Detection of trisomy 21 and translocations of chromosome 4. Proc Natl Acad Sci USA. 1988; 87:9138–9142.
4. Southern E. Detection of specific sequences among DNA fragments separated by gel electrophoresis. J Mol Biol. 1975; 98:503–517.
5. Chu G, Voltrath D, Davis RW. Separation of large DNA molecules by contour-clamped homogeneous electric fields. Science. 1986; 234:1582–1585.
6. Saiki R, Bugawan T, Horn G, et al. Analysis of enzymaticatly amplified betaglobin and HLA-DQ DNA with allele-specific oligonucleotide probes. Nature. 1986; 324:163–166.
7. Saiki RK, Gelfand DH, Stoffel S, et al. Primer-directed enzymatic amplification of DNA with a thermostable DNA polymerase. Science. 1988; 239:487–491.
8. Myers RM, Larin Z, Maniatis T. Detection of single base substitutions by ribonuclease cleavage at mismatches in RNA:DNA duplexes. Science. 1985; 230:1242–1246.
9. Veelken H, Tycko B, Sklar J. Sensitive detection of clonal antigen receptor gene rearrangements for the diagnosis and monitoring of lymphoid neoplasms
by a polymerase chain reaction mediated ribonuclease protection assay. Blood. 1991; 78:1318–1326.
10. Myers RM, Fischer SG, Lerman LS, Maniatis T. Detection and localization of single base changes by denaturing gradient gel electrophoresis. Methods Enzymol. 1987; 155:501–527.
11. Orita M, Iwahana H, Kanazawa H, Hayashi K, Sekiya T. Detection of polymorphisms of human DNA by gel electrophoresis as single-strand conformation polymorphisms. Proc Natl Acad Sci USA. 1989; 86:2766–2770.
12. Orita M, Suzuki Y, Sekiya T, Hayashi K. Rapid and sensitive detection of point mutations and DNA polymorphisms using the polymerase chain reaction. Genomics. 1989; 5:874–879.
13. Cotton RGH, Rodrigues NR, Campbell RD. Reactivity of cytosine and thymine in single-base-pair mismatches with hydroxylamine and osmium tetroxide and its application to the study of mutations. Proc Natl Acad Sci USA. 1988; 86:4397–4401.
14. Dahl H-HM, Lamande SR, Cotton RGH, Bateman JF. Detection and localization of base changes in RNA using a chemical cleavage method. Anal Biochem. 1989; 183:263–268.
15. Picker LJ, Weiss LM, Medeiros JL, et al. Immunophenotypic criteria for the diagnosis of non-Hodgkin's lymphoma. Am J Path. 1987; 128:181–201.
16. Knowles DM. Immunophenotypic and antigen receptor gene rearrangement analysis in T cell neoplasia. Am J Path. 1989; 134:761–785.
17. Smith LJ, Curtis JE, Messner HA, et al. Lineage infidelity in acute leukemia. Blood. 1983; 61:1138.
18. Stass SA, Mirro J. Lineage heterogeneity in acute leukemia: Acute mixed-lineage leukemia and lineage switch . Clin Haematol. 1986; 15:811.
19. Greaves MF, Chan LC, Furley SM, et al. Lineage promiscuity in hemopoietic differentiation and leukemia. Blood. 1986; 67:1.
20. Del Vecchio L, Schiavone EM, Ferrara F, et al. Immunodiagnosis of acute leukemia displaying ectopic antigens: Proposal for a classification of promiscuous phenotypes. Am J Hematol. 1989; 31:173–180.
21. Nowell P, Hungerford D. A minute chromosome in human granulocytic leukemia. Science. 1960; 132:1497.
22. Rowley JD. A new consistent chromosomal abnormality in chronic myelogenous leukemia identified by quinacrine fluorescence and Giemsa staining. Nature. 1973; 243:290–293.
23. Hagemeijer A, Bootsma D, Spurr N, et al. A cellular oncogene is translocated to the Philadelphia chromosome in chronic myelocytic leukemia. Nature. 1982; 300:765–767.
24. Groffen J, Stevenson J, Heisterkamp N, et al. Philadelphia chromosome breakpoints are clustered within a limited region, bcr, on chromosome 22. Cell. 1984; 36:93–99.
25. Heisterkamp N, Stam K, Groffer J, et al. Structural organization of the ber gene and its role in the Philadelphia translocation. Nature . 1985; 315:758–761.
26. Carroll WL, Schwartz AL. Molecular Oncology. In: Fernbach DJ and Vietti TJ, eds. Clinical Pediatric Oncology. 5th ed. St. Louis, MO: C.V. Mosby; 1991: 29–68.
27. Collins S, Grondine M. Rearrangement and amplification of c-abl sequences in the human CML cell line K562. Proc Natl Acad Sci USA. 1983; 80:4813–4817.
28. Konopka J, Watahabe S, Witte O. An alteration of the human c-abl protein K562 leukemia cells unmasks associated tyrosine kinase activity. Cell. 1984; 37:1035–1042.
29. McLaughlin J, Chianesc E, Witte O. In vitro transformation of immature hematopoietic cells by the p210 ber/abl oncogene product of the Philadelphia chromosome. Proc Natl Acad Sci USA. 1987; 84:6558–6562.
30. de Klein A, Hagemeijer A. Cytogenetic and molecular analysis of the Philadelphia translocation in chronic myelogenous leukemia. Cancer Surv. 1984; 3:515–529.
31. Ganessan TS, Rassool F, Gino A-P, et al. Rearrangement of the bcr gene in Ph chromosome-negative chronic myelogenous leukemia. Blood. 1986; 68:957–960.
32. Haber L, Childs C, Hirsch-Ginsberg C, et al. Strategy for breakpoint cluster region analysis in chronic myelogenous leukemia in a routine clinical laboratory. Am J Clin Path. 1990; 94:762–767.
33. Blennerhassett GT, Furth ME, Anderson P, et al. Clinical evaluation of DNA probe assay for Philadelphia translocation in chronic myelogenous leukemia. Leukemia. 1988; 2:648–657.
34. Tkachuk D, Westbrook C, Andreeff M, et al. Detection of bcr-abl fusion in chronic myelogenous leukemia by in situ hybridization. Science. 1990; 250:559–562.
35. Kurzrock R, Shtalrid M, Gutterman JU, Talpaz M. Molecular diagnostics of chronic myelogenous leukemia and Philadelphia chromosome-positive acute leukemia. Cancer Cells. 1989; 7:9–13.
36. Kurzrock R, Gutterman JU, Talpaz M. The molecular genetics of Philadelphia chromosome-positive leukemias. N Engl J Med. 1988; 319:990–998.
37. Dube ID, Carter RF, Pinkerton PH. Chromosomal abnormalities in chronic myelogenous leukemia. A model for acquired chromosome changes in haematological malignancies. Tumor Biol. 1990; 11:3–24.
38. Ahuja H, Bar-Eli M, Advani SH, et al. Alterations in the p53 gene and clonal evolution of the blast crisis of chronic myelogenous leukemia. Proc Natl Acad Sci USA. 1989; 86–7893–6787.
39. Mashal R, Shtalrid M, Talpaz M, et al. Rearrangement and expression of p53 in the chronic phase and blast crisis of chronic myelogenous leukemia. Blood. 1990; 75;180–189.
40. Mills KI, MacKenzie ED, Birnie GD. The site of the breakpoint within the bcr is a prognostic factor in Philadelphia positive CML patients. Blood. 1988; 72:1237–1241.
41. Johansson B, Mertens F, Florentos T, et al. Remarkably long survival of a patient with Ph1-positive chronic myeloid leukemia and 5' bcr rearrangement. Leukemia. 1990; 4:448–449.
42. Jaubert J, Martiat P, Dowding C, et al. The position of the M-BCR breakpoint does not predict the duration of chronic phase or survival in chronic myeloid leukemia. Br J Haematol. 1990; 74:30–35.
43. Ogawa H, Sugiyama H, Soma T, et al. No correlation between locations of bcr breakpoints and clinical states in Ph1-positive CML patients. Leukemia. 1989; 3:492–496.
44. Nelkin BD, Przepiorka D, Burke PJ, et al. Abnormal methylation of the calcitonin gene marks progression of CML. Blood. 1991; 77:2431–2434.
45. Malinen T, Palotie A, Pakkala S, et al. Acceleration of CML correlates with calcitonin gene hypermethylation. Blood. 1991; 77:2435–2440.
46. Kawasaki ES, Clark SS, Coyne MY, et al. Diagnosis of chronic myelogenous leukemia and acute leukemia by detection of leukemia-specific mRNA sequences amplified in vitro. Proc Natl Acad Sci USA. 1988; 85:5689–5694.
47. Pignson JM, Henn T, Amselem S, et al. Frequent detection of minimal residual disease by use of polymerase chain reaction in long term survivors after bone marrow transplant for chronic myelogenous leukemia. Leukemia. 1990; 4:83–86.
48. Rothe MS, Antin JH, Bingham EL, Ginsburg D. Detection of Philadelphia chromosome-positive cells by polymerase chain reaction following bone marrow transplant for chronic myelogenous leukemia. Blood. 1989; 74:882–885.
49. Gabert J, Thuret I, Lafage M, et al. Detection of residual bcr/abl translocation by polymerase chain reaction in chronic myelogenous leukemia patients after bone marrow transplant. Lancet. 1989; ii: 1125–1128.
50. Hughes TP, Goldman JM. Biologic importance of residual leukemia cells after BMT for CML: does the polymerase chain reaction help? Bone Marrow Transplant. 1990; 5:3–6.
51. Talpaz M, Kantarjian H, Kurzrock R, et al. Interferon alpha produces sustained cytogenetic responses in chronic myelogenous leukemia. Philadelphia chromosome-positive patients. Ann Int Med. 1991; 114:532–538.
52. Lee M-S, LeMaistre A, Kantarjian HM, et al. Detection of two alternative BCR/ABL mRNA junctions and minimal residual disease in Philadelphia chromosome positive chronic myelogenous leukemia by polymerase chain reaction. Blood. 1989; 73:2165–2170.
53. Szczylik C, Skorski T, Nicolaides NC, et al. Selective inhibition of leukemia cell proliferation by BCR-ABL antisense oligodeoxynucleotides. Science. 1991; 253:562–565.
54. Trump DL, Mann RB, Phelps R, et al. Richter's syndrome: Diffuse histiocytic lymphoma in patients with chronic lymphocytic leukemia. Am J Med. 1980; 68:539–548.
55. Foucar K, Rydell RE. Richter's syndrome in chronic lymphocytic leukemia. Cancer. 1980; 46:118–134.
56. Fitzgerald PH, McEwan CM, Hamer JW, Beard MEJ. Richter's syndrome with identification of marker chromosomes. Cancer. 1980; 46:135–138.
57. Knuutila S, Elonen E, Teerenhovi L, et al. Trisomy 12 in B cells of patients with B-cell chronic lymphocytic leukemia. N Engl J Med. 1986; 314:865.
58. Juliusson G, Oscler DG, Fitchett M, et al. Prognostic subgroups in B-cell CLL defined by specific chromosomal abnormalities. N Engl J Med. 1990; 323:720–724.
59. Anastasi JA, Le Beau MM, Vardiman JW, et al. Detection of trisomy 12 in chronic lymphocytic leukemia by fluorescence in situ hybridization to inter-phase cells: A simple and sensitive method. Submitted for publication.
60. Bird ML, Ueshima Y, Rowley JD, et al. Chromosome abnormalities in B cell chronic leukemia and their clinical correlations. Leukemia . 1989; 3:182–191.
61. Losada AP, Wessman M, Tiainen M, et al. Trisomy 12 in chronic lymphocytic leukemia: An interphase cytogenetic study. Blood. 1991; 78:775–779.
62. Rowley J. Recurring chromosomal abnormalities in leukemia and lymphoma. Sem Hematol. 1990; 27:122–136.
63. Hermans A, Heisterkamp N, von Lindern M, et al. Unique fusion of bcr and cab1 genes in Philadelphia chromosome-positive acute lymphoblastic leukemia. Cell. 1987; 51:31–40.
64. Selleri L, von Lindern M, Hermans A, et al. Chronic myeloid leukemia may be associated with several bcr-abl transcripts including the acute lymphoid leukemia-type 7 kb transcript. Blood. 1990; 75:1146–1153.
65. Westbrook CA, Rubin CM, Carrino JJ, et al. Long range mapping of the Philadelphia chromosome by pulse field gel electrophoresis. Blood. 1988; 71:697–702.
66. Strong RC, Korsmeyer SJ, Parkin JL, et al. Human acute leukemia line with the t(4; 11) chromosomal rearrangement exhibits B lineage and monocytic characteristics. Blood. 1986; 67:391–397.
67. Nourse J, Mellentin JD, Galili N, et al. Chromosomal translocation t(1;19) results in synthesis of a homeobox fusion mRNA that codes for a potential chimeric transcription factor. Cell. 1990; 60:535–545.
68. Kamps MP, Murre C, Sun XH, Baltimore D. A new homeobox gene contributes the DNA binding domain of the t(1;19) translocation protein in pre-B ALL. Cell. 1990; 60:547–555.
69. Yamada T, Craig JM, Hawkins JM, et al. Molecular investigation of 19p13 in standard and variant translocations; the E12 probe recognizes the 19p13 breakpoint in cases with t(1;19) and acute leukemia other than pre-B immunophenotype. Leukemia. 1990; 5:36–40.
70. Saltman DL, Mellentin JD, Smith SD, Cleary ML. Mapping of translocation breakpoints on the short arm of chromosome 19 in acute leukemia by in situ hybridization. Genes Chromosomes Cancer. 1990; 2:259–265.
71. Care A, Cianetti L, Giannpaolo A, et al. Translocation of c-myc into the immunoglobulin heavy chain locus in human acute B cell leukemia. EMBO J. 1986; 5:905–911.
72. Castella A, Davey FR, Kurec AS, Nelson DA. The presence of Burkitt-like cells in non-Burkitt's neoplasms. Cancer. 1982; 50:1764–1770.
73. Imamura N, Mitasiwa DM, Ota H, et al. FAB L3 type of B-cell acute lymphoblastic leukemia (B-ALL) without chromosome abnormalities. Am J Hematol. 1990; 35:216–218.
74. Showe LC, Croce CM. The role of chromosomal translocation in B-and T-cell neoplasia. Ann Rev Immunol. 1987; 5:253–277.
75. Brown L, Cheng JT, Chen Q, et al. Site-specific recombination of the tal-1 gene is a common occurrence in human T cell leukemia. EMBO J. 1990; 9:3343–3351.
76. Aplan PD, Lombardi DP, Ginsberg AM, et al. Disruption of human SCL locus by ''illegitimate'' V-(D)-J recombinase activity. Science. 1990; 250:1426–1429.
77. Third International Workshop on Chromosomes in Leukemia: Clinical signifi-
cance of chromosomal abnormalities in acute lymphoblastic leukemia. Cancer Genet Cytogenet. 1981; 4:111–137.
78. Bloomfield CD, Secker-Walker LM, Goldman AI, et al. Six-year follow-up of the significance of karyotype in acute lymphoblastic leukemia. Cancer Genet Cytogenet. 1989; 40:171–185.
79. Cancer and Leukemia Group B (unpublished). Data from CD Bloomfield.
80. Fletcher JA, Kimball VM, Lynch E, et al. Prognostic implications of cytogenetic studies in an intensively treated group of children with acute lymphoblastic leukemia. Blood. 1989; 74:2130–2135.
81. Fletcher JA, Lynch EA, Kimball VM, et al. Translocation (9;22) is associated with extremely poor prognosis in intensively treated children with acute lymphoblastic leukemia. Blood. 1991; 77:435–439.
82. Yamada M, Wasserman R, Lange B, et al. Minimal residual disease in childhood B-lineage lymphoblastic leukemia. Persistence of leukemic cells during the first months of treatment. N Engl J Med. 1990; 323:448–455.
83. Tycko B, Palmer JD, Link MP, et al. Polymerase chain reaction amplification of rearranged antigen receptor genes using junction-specific oligonucleotides: Possible application for detection of minimal residual disease in ALL. Cancer Cells. 1989; 7:47–52.
84. Veelken H, Tycko B, Sklar J. Sensitive detection of clonal antigen receptor gene rearrangements for the diagnosis and monitoring of lymphoid neoplasia by a PCR-mediated ribonuclease protection assay. Blood; in press.
85. Rowley JD. Identification of a translocation with quinacrine fluorescence in a patient with acute leukemia. Annales de Genetique. 1973; 16:109–112.
86. Fourth International Workshop on Chromosomes in Leukemia. Cancer Genet Cytogenet. 1984; 11:249–360.
87. Gao J, Erickson P, Gardiner K, et al. Isolation of a yeast artificial chromosome spanning the 8;21 translocation breakpoints t(8;21)(q22;q22.2) in acute myelogenous leukemia. Proc Natl Acad Sci USA. 1991; 88:4882–4886.
88. Rowley JD, Golomb HM, Vardiman J, et al. Further evidence for a non-random chromosomal abnormality in acute promyelocytic leukemia. Int J Cancer. 1977; 20:869–872.
89. Borrow J, Goddard AD, Sheer D, Solomon E. Molecular analysis of acute promyelocytic leukemia breakpoint cluster region on chromosome 17. Science. 1990; 249:1577–1580.
90. Lemons R, Eilender D, Waldmann R, et al. Cloning and characterization of the t(15;17) translocation bp region in APML. Genes Chromosomes Cancer. 1990; 2:79–87.
91. de The H, Chomienne C, Lanotte M, et al. The t(15;17) translocation of acute promyelocytic leukemia fuses the retinoic acid receptor alpha to a novel transcribed locus. Nature. 1990; 347:558–561.
92. Huang ME, Ye YC, Chai JR, et al. Use of all trans-retinoic acid in treatment of acute promyelocytic leukemia. Blood. 1988; 72:567–572.
93. Warrell RP, Frankel SR, Miller WH Jr., et al. Differentiation therapy of acute promyelocytic leukemia with tretinoin (all-trans -retinoic acid). N Engl J Med. 1991; 324:1385–1393.
94. Golomb HM, Rowley J, Vardiman JW, et al. "Microgranular" acute promyelocytic
leukemia: a distinct clinical, ultrastructural, and cytogenetic entity. Blood. 1980; 55:253–259.
95. Biondi A, Rambald A, Alcalay M, et al. RAR-alpha gene rearrangements as a genetic marker for diagnosis and monitoring in acute programilocytic leukemia. Blood. 1991; 77:1418–1422.
96. Berger R, Bernheim A, Sigaux F, et al. Acute monocytic leukemia chromosome studies. Leuk Res. 1982; 6:17–26.
97. Larson RA, Williams SF, LeBeau MM, et al. Acute myelomonocytic leukemia with abnormal eosinophils and inv(16) or t(16;16) has a favorable prognosis. Blood. 1986; 68:1242–1249.
98. von Lindern M, Poustka A, Leroch H, Grosveld G. The (6;9) chromosome translocation, associated with a specific subset of acute nonlymphocytic leukemia, leads to aberrant transcription of a target gene on 9q34. Molec Cell Biol. 1990; 10:4016–4026.
99. Bitter MA, Neilly ME, Le Beau MM, et al. Rearrangement of chromosome 3 involving bands 3q21 and 3q26 are associated with normal or elevated pH counts in ANLL. Blood. 1985; 66:1362–1370.
100. Ratain MJ, Kaminer LS, Bitran JD, et al. Acute non-lymphocytic leukemia following etoposide and cisplatin combination chemotherapy for advanced non-small-cell carcinoma of the lung. Blood. 1987; 70:1412–1417.
101. Keating MS, Smith TL, Kantarjian H, et al. Cytogenetic pattern in acute myelogenous leukemia: A major reproducible determinant of outcome. Leukemia. 1988; 2:403–412.
102. Yunis JJ, Rydell RE, Oken MM, et al. Refined chromosome analysis as an independent prognostic indicator in de novo myelodysplastic syndromes. Blood. 1986; 67:1721–1730.
103. Hirai H, Kobayashi Y, Mano, H, et al. A point mutation of codon 13 of the N-ras oncogene in myelodysplastic syndrome. Nature. 1987; 327:430–432.
104. Liu E, Hjelle B, Morgan R, et al. Mutations of the Kirsten-ras proto-oncogene in human preleukemia. Nature. 1987; 330:186–188.
105. Hirai H, Okada M, Mizoguchi H, et al. Relationship between an activated N-ras oncogene and chromosomal abnormality during leukemic progression from myelodysplastic syndrome. Blood. 1988; 71:256-258.
106. Yunis JJ, Boot AJ, Mayer MG, Bos JL. Mechanisms of ras mutation in myelodysplastic syndrome. Oncogene. 1989; 4:609–614.
107. Carter G, Hughes D, Clark R, et al. Ras mutations in patients following cytotoxic therapy for lymphoma. Oncogene. 1990; 5:411–416.
108. Ridge SA, Worwood M, Oscier D, et al. FMS mutations in myelodysplastic, leukemic, and normal subjects. Proc Natl Acad Sci USA. 1990; 87:1377–1380.
109. Levy R, Warnke R, Dorfman RF, Haimovich J. The monoclonality of human B-cell lymphomas. J Exp Med. 1972; 145:1014–1028.
110. Sklar J, Weiss LM. Application of antigen receptor gene rearrangement to the diagnosis and characterization of lymphold neoplasms. Ann Rev Med. 1988; 39:315–334.
111. Fishleder A, Tubbs R, Hesse B, Levine H. Uniform detection of immunoglobulin gene rearrangement in benign lymphoepithelial lesions. N Engl J Med. 1988; 316:1118–1121.
112. Weiss LM, Wood G, Treis M, et al. Clonal T cell populations in lymphomatoid papulosis: evidence for a lymphoproliferative origin for a clinically benign disease. N Engl J Med. 1986; 315:475–479.
113. Croce CM, Nowell PC. Molecular basis of B cell neoplasia. Blood. 1985; 65:1–7.
114. Hulaska FG, Russo G, Kaut J, et al. Molecular resemblance of an AIDS-associated lymphoma and endemic Burkitt's lymphoma: implications for their pathogenesis. Proc Natl Acad Sci USA. 1989; 86:8907–8911.
115. Pelicci P-G, Knowles DMI, McGrath I, et al. Chromosomal breakpoints and structural alterations of the c-myc locus differ in endemic and sporadic forms of Burkitt lymphoma. Proc Natl Acad Sci USA. 1986; 83:2984–2988.
116. Dalla-Favera R. Unpublished data.
117. Cesarman E, Dalla-Favera R, Bentley D, Groudine M. Mutations in the first exon are associated with altered transcription of c-myc in Burkitt lymphoma. Science. 1987; 238:1272–1275.
118. Offit K, Jhanwar SC, Ladanyi M, et al. Cytogenetic analysis of 434 consecutively ascertained specimens of non-Hodgkin's lymphoma: correlations between recurrent abberations, histology, and exposure to cytotoxic treatment. Genes Chromosomes Cancer. 1991; 3:189–201.
119. Tsujimoto Y, Finger LR, Yunis J, et al. Cloning of the chromosomal breakpoints of neoplastic B cells with the t(14;18) chromosomal translocation. Science. 1984; 226:1097–1099.
120. Cleary ML, Sklar J. Nucleotide sequence of a t(14;18) chromosomal bp in follicular lymphoma and demonstration of a breakpoint cluster region near a transcriptionally active locus on chromosome 18. Proc Natl Acad Sci USA. 1985; 82:7439–7443.
121. Bakhshi A, Jensen JP, Goldman P, et al. Cloning the chromosome bp of t(14;18) in human lymphomas: clustering around JH on chromosome 14 and near a transcriptional unit on chromosome 18. Cell. 1985; 41:899–906.
122. Hockenberry D, Nuuez G, Milliman C, et al. Bcl-2 is an inner mitochondrial membrane protein that blocks programmed cell death. Nature. 1990; 348:334–336.
123. Hockenberry DM, Zutter M, Hickey W, et al. Bcl-2 protein is topographically restricted to tissues characterized by apoptotic cell death. Proc Natl Acad Sci USA. 1991; 88:6961–6965.
124. Cleary ML, Galili N, Sklar J. Detection of a second t(14;18) breakpoint cluster region in follicular lymphoma. J Exp Med. 1986; 164:305–310.
125. Tsujimoto Y, Bashir MM, Givol I, et al. DNA rearrangements in human follicular lymphoma can involve the 5' or the 3' region of the bel-2 gene. Proc Natl Acad Sci USA. 1987; 84:1329–1331.
126. Crescenzi M, Seto M, Herzig GP, et al. Thermostable DNA polymerase chain amplification of t(14;18) chromosome breakpoints and detection of minimal residual disease. Proc Natl Acad Sci USA. 1988; 85:4869–4873.
127. Ngan BY, Nourse J, Cleary ML. Detection of chromosomal translocation t(14;18) within the minor cluster region of bcl-2 by polymerase chain reaction and direct genomic sequencing of the enzymatically amplified DNA in follicular lymphomas. Blood. 1989; 73:1759–1762.
128. Pezzella F, Tse AGD, Cordell JL, et al. Expression of the Bcl-2 oncogene protein is not specific for the 14; 18 chromosomal translocation. Am J Pathol. 1990; 137:225–232.
129. Zutter M, Hockenberry D, Silverman GA, Korsmeyer SJ. Immunolocalization of the Bcl-2 protein within hematopoietic neoplasms. Blood. 1991; 78:1062–1068.
130. Ngan B-Y, Chen-Levy Z, Weiss LM, et al. Expression in non-Hodgkin's lymphoma of the Bcl-2 protein associated with the t(14;18) chromosomal translocation. N Eng J Med. 1988; 318:1638–1644.
131. Lee M-S, Chang K-S, Cabanillas F, et al. Detection of minimal residual cell carrying the t(14;18) by DNA sequence amplification. Science. 1987; 237:175–178.
132. Limpens J, de Jong D, Voetdijk AMH, et al. Translocation t(14;18) in benign B lymphocytes. Blood. 1990; 76:2379.
133. Weisenburger DD, Kim H, Rappaport H. Mantle zone lymphoma: A follicular variant of intermediate lymphocytic lymphoma. Cancer. 1982; 49:1429–1438.
134. van den Berghe H, Parloir C, David G, Michaux JL, Sokal G. A new characteristic karyotypic anomaly in lymphoproliferative disorders. Cancer. 1979; 44:188.
135. Tsujimoto Y, Yunis J, Onorato-Showe L, et al. Molecular cloning of the chromosomal breakpoint of B-cell lymphomas and leukemias with the t(11;14) chromosome translocation. Science. 1984; 224:1403–1406.
136. Williams ME, Meeker TC, Swerdlow SH. Rearrangement of the chromosome 11 bcl-1 locus in centrocytic lymphoma: Analysis with multiple breakpoint probes. Blood. 1991; 78:493–498.
137. Levine EG, Jujena S, Arthur D, et al. Sequential karyotypes in NHL: Their nature and significance. Genes Chromosomes Cancer. 1990; 1:270–280.
138. Cabinillas F, Pathak S, Grant G, et al. Refractoriness to chemotherapy and poor survival related to abnormalities of chromosomes 17 and 7 in lymphoma. Am J Med. 1989; 87:167–172.
139. Mitelman F. Catalog of Chromosome Aberrations in Cancer. 4th ed. New York, NY: Wiley-Liss, 1991.
140. Sandberg AA. The Chromosomes in Human Cancer and Leukemia. 2nd ed. Elsevier, 1990.
141. Emanuel A, Szucs S, Weier WH-U, Kovacs G. Clonal aberrations of the X and Y chromosomes and chromosomes 7 and 10 in normal kidney tissue of patients with renal cell tumors. Genes Chromosomes Cancer ; in press.
142. Lindstrom E, Salford LG, Heim S, et al. Trisomy 7 and sex chromosome loss are not representative of tumor parenchyma cells in the malignant glioma. Genes Chromosomes Cancer; in press.
143. Israel MA, Miser JS, Triche TJ, et al. Neuroepithelial tumors. In: Pizzo PA, Poplack DG, eds. Principles and Practice of Pediatric Oncology. Philadelphia, PA: JB Lippincott, 1989: 694.
144. Brodeur GM, Sekhon GS, Goldstein MN. Chromosomal aberrations in human neuroblastomas. Cancer. 1977; 40:2256–2263.
145. Fong CT, Dracopoli N, White P, et al. Loss of heterozygosity for chromosome 1p in human neuroblastomas: Correlation with N-myc amplification. Proc Natl Acad Sci USA. 1989; 86:3753–3757.
146. Cox D, Yuncken C, Spriggs A. Minute chromatin bodies in malignant tumors of childhood. Lancet. 1965; ii:55–58.
147. Brodeur GM, Fong CT. Molecular biology and genetics of human neuroblastoma. Cancer Genet Cytogenet. 1989; 41:153–174.
148. Biedler JL, Spengler BA. A novel chromosome abnormality in human neuroblastoma and antifolate-resistant chinese hamster cell lines in culture. J Natl Cancer Inst. 1976; 57:683–695.
149. Schwab M, Alitalo K, Klempnauer KH, et al. Amplified DNA with limited homology to myc cellular oncogene is shared by human neuroblastorna cell lines and a neuroblastoma tumor. Nature. 1983; 305:245–248.
150. Turc-Carel C, Aurias A, Magneret F, et al. Chromosomes in Ewing's sarcoma. I. An evaluation of 85 cases and remarkable consistency of t(11;22)(q24;q12). Cancer Genet Cytogenet. 1988; 32:229–238.
151. Mugneret F, Lizard S, Aurias A, Turc-Carel C. Chromosomes in Ewing's sarcoma. II. Non random additional changes trisomy 8 and der(16) t(1;16). Cancer Genet Cytogenet. 1988; 32:239–245.
152. Wang-Wuu S, Sonkup S, Ballard E, et al. Chromosomal analysis of sixteen human rhabdomyosarcomas. Cancer Res. 1988; 983–987.
153. Granberg I, Mark J. The chromosomal aberration of double-minutes in a human embryonic rhabdomyosarcoma. Acta Cytol. 1971; 15:42–45.
154. Douglass EC, Valentine M, Etcubanas E, et al. A specific chromosomal abnormality in rhabdomyosarcoma. Cytogenet Cell Genet. 1987; 45:148–155.
155. Douglass EC, Rowe ST, Valentine M, et al. Variant translocations of chromosomes 13 in alveolar rhabdomyosarcoma. Genes Chromosomes Cancer; in press.
156. Biegel JA, Meek RS, Parmiter AH, Conard K, Emanuel BS. Chromosomal translocation t(1;13)(p36;q14) in a case of rhabdomyosarcoma. Genes Chromosomes Cancer; in press.
157. Brodeur GM, Seeger RC, Schwab M, et al. Amplification of N-myc in untreated human neuroblastomas correlates with advanced disease stage. Science. 1984; 224:1121–1124.
158. Turc-Carel C, Dal Cin P, Limon J, et al. Involvement of chromosome X in primary cytogenetic change in human neoplasia: nonrandom translocation in synovial sarcoma. Proc Natl Acad Sci USA. 1987; 84:1981–1985.
159. Turc-Carel C, Limon J, Dal Cin P, et al. Cytogenetic studies of adipose tissue tumors. II. Recurrent reciprocal translocation t(12;16)(q13;p11) in myxoid liposarcomas. Cancer Genet Cytogenet. 1986; 23:291–299.
160. Orndal C, Mandahl N, Rydholm A, et al. t(9;22) as a specific clonal chromosomal abnormality in extraskeletal myxoid chondrosarcoma. Manuscript in preparation.
161. Mandahl N, Heim S, Willen H, et al. Characteristic karotypic anomalies identify subtypes of malignant fibrous histiocytoma. Genes Chromosomes Cancer. 1989; 1:9–14.
162. Riccardi VM, Elder DW. Multiple cytogenetic aberrations in neurofibrosarcomas complicating neurofibromatosis. Cancer Genet Cytogenet. 1986; 23:199–209.
163. Fletcher JA, Lipinski KK, Corson JM, Morton CC. Cytogenetics of peripheral nerve sheath tumors. Cancer Genet Cytogenet. 1989; 41:224 (abstract).
164. Rydholm A, Mandahl N, Heim S, et al. Malignant fibrous histocytomas with a 19p+ marker chromosome have increased relapse rate. Genes Chromosomes Cancer. 1990; 2:296–299.
165. Fletcher JA, Kozakewich HP, Hoffer FA, et al. Diagnostic relevance of clonal cytogenetic aberrations in malignant soft-tissue tumors. N Engl J Med. 1991; 324:436–442.
166. Fletjer WL, Li FP, Antman KH, Testa JR. Recurring loss of chromsomes 1, 3 and 22 in malignant mesothelioma: possible sites of tumor suppressor genes. Genes Chromosomes Cancer. 1989; 1: 148–154.
167. Zech L, Bergh J, Nilsson K. Karyotypic characterization of established cell lines and short-term cultures of human lung cancer. Cancer Genet Cytogenet. 1985; 15:335–347.
168. Whang-Peng J, Bunn PA Jr, Kao-Shan CS, et al. A nonrandom chromosomal abnormality, del 3p(14–23) in human small cell lung cancer (SCLC). Cancer Genet Cytogenet. 1982; 6:11–134.
169. Lukeis R, Irving L, Garson M, Hasthorpe S. Cytogenetics of non-small cell lung cancer: analysis of consistent non-random abnormalities. Genes Chromosomes Cancer. 1990; 2:116–124.
170. Miura I, Siegfried JM, Resau J, et al. Chromosomal alterations in 21 non-small cell lung carcinomas. Genes Chromosomes Cancer. 1990; 2:328–338.
171. Seeger RC, Brodeur GM, Sather H, et al. Association of multiple copies of the N-myc oncogene with rapid progression of neuroblastomas. N Engl J Med. 1985; 313:1111–1116.
172. Brodeur GM. Neuroblastoma—clinical applications of molecular parameters. Brain Pathol. 1990; 1:47–54.
173. Slamon DJ, Godolphin W, Jones LA, et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science. 1989; 244:707–712.
174. Slamon DJ, Clark GM, Wong SG, et al. Human breast cancer: Correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science. 1987; 235:177–182.
175. Wright C, Angus B, Nicholson S, et al. Expression of the c-erbB2 oncoprotein: A prognostic indicator in human breast cancer. Cancer Res. 1989; 49:2087–2092.
176. Sainsbury JR, Farndon JR, Needham GK, et al. Epidermal growth-factor receptor status as predictor of early recurrence of and death from breast cancer. Lancet. 1987; 1:1398–1402.
177. Tandon AK, Clark GM, Chamness GC, et al. Cathepsin D and prognosis in breast cancer. N Engl J Med. 1990; 322:297–302.
178. Steeg PS, Bevilacqua G, Kopper L, et al. Evidence for a novel gene associated with low tumor metastatic potential. J Natl Cancer Inst. 1988; 80:200–204.
179. Bevilacqua G, Sobel ME, Liotta LA, et al. Association of low nm23 RNA levels in human primary infiltrating ductal breast carcinomas with lymph node involvement and other histo-pathological indicators of high metastatic potential. Cancer Res. 1989; 49:5185–5190.
180. Hennessey C, Henry JA, May FEB, et al. Expression of the anti-metastic gene nm-23 in human breast cancer: Association with good prognosis. J Natl Cancer Inst. 1991; 83:281–285.
181. Wright C, Angus B, Nicholson S, et al. Expression of c-erbB-2 oncoprotein: A prognostic indicator in human breast cancer. Cancer Res. 1989; 49:2087–2090.
182. Paik S, Hazan R, Fisher ER, et al. Pathologic findings from the national surgical adjuvant breast and bowel project: Prognostic significance of erbB-2 protein overexpression in primary breast cancer. J Clin Oncol. 1990; 8:103–112.
183. Ro J, El-Naggar A, Ro JY, et al. c-erbB-2 amplification in node-negative human breast cancer. Cancer Res. 1989; 49:6941–6944.
184. Paterson MC, Dietrich KD, Danyluk J, et al. Correlation between c-erbB-2 amplification and risk of recurrent disease in node-negative breast cancer. Cancer Res. 1991; 51:556–567.
185. Gullick WJ, Love SB, Wright C, et al. c-erbB-2 protein overexpression in breast cancer is a risk factor in patients with involved and uninvolved lymph nodes. Br J Cancer. 1991; 63:434–438.
186. Winstanley J, Cooke T, Murray GD, et al. The long term prognostic significance of c-erbB-2 in primary breast cancer. Br J Cancer. 1991; 63:447–450.
187. Fisher B, Redmond C, Fisher ET, et al. Relative worth of estrogen and pro-gesterone receptor and pathologic characteristics of differentiation as indicators of prognosis in node negative breast cancer patients: Findings from National Surgical Adjuvant Breast and Bowel Project protocol B-06. J Clin Oncol. 1988; 6:1076–1087.
188. Dressler LG, Seamer MT, Owens MA, et al. DNA flow cytometry and prognostic factors in 1331 frozen breast cancer specimens. Cancer . 1988; 62:420–427.
189. Clark GM, Dressler LG, Owens MA, et al. Prediction of relapse or survival in patients with node-negative breast cancer by DNA flow cytometry. N Engl J Med. 1989; 320:627–637.
190. Weidner N, Semple JP, Welch WR, Folkman J. Tumor angiogenesis and metastasis—correlation in invasive breast carcinoma. N Engl J Med. 1991; 324:1–8.
191. Brauch H, Johnson B, Hovis J, et al. Molecular analysis of the short arm of chromosome 3 in small-cell and non-small-cell carcinoma of the lung. New Engl J Med. 1987; 317:1109–1113.
192. Mori N, Yokota J, Oshimura M, et al. Concordant deletions of chromosome 3p and loss of heterozygosity for chromosomes 13 and 17 in small cell lung carcinoma. Cancer Res. 1989; 15:5130–5135.
193. Morstyn G, Brown J, Novak U, et al. Heterogeneous cytogenetic abnormalities in small cell lung cancer cell lines. Cancer Res. 1987; 15:3322–3327.
194. Kok K, Osinga J, Carritt B, et al. Deletion of a DNA sequence at the chromosomal region 3p21 in all major types of lung cancer. Nature. 1987; 330:578–581.
195. Naylor SL, Johnson BE, Minna JD, Sakaguchi AY. Loss of heterozygosity of chromosome 3p markers in small-cell lung cancer. Nature. 1987; 329:451–454.
196. Yokota J, Wada M, Shimosato Y, Terada M, Sugimura T. Loss of heterozygosity on chromosomes 3, 13, and 17 in small-cell carcinoma and on chromosome 3 in adenocarcinoma of the lung. Proc Natl Acad Sci USA. 1987; 84:9252–9256.
197. Harbour JW, Lai SL, Whang-Peng J, et al. Abnormalities in structure and expression of the human retinoblastoma gene in SCLC. Science. 1988; 241:353–357.
198. Nigro JM, Baker SJ, Preisinger AC, et al. Mutations in the p53 gene occur in diverse human tumor types. Nature. 1989; 342:705–708.
199. Takahashi T, Nau MM, Chiba I, et al. p53: A frequent target for genetic abnormalities in lung cancer. Science. 1989; 246:491–494.
200. Iggo R, Gatter K, Bartek J, Lane D, Harris AL. Increased expression of mutant forms of p53 oncogene in primary lung cancer. Lancet. 1990; 335:675–679.
201. Rodenhuis S, Slebos RJ, Boot AJ, et al. Incidence and possible clinical significance of K-ras oncogene in adenocarcinoma of the human lung. Cancer Res. 1988; 48:5738–5741.
202. Slebos RJC, Kibbelaar RE, Dalesio O, et al. K-ras oncogene activation as a prognostic marker in adenocarcinoma of the lung. New Engl J Med. 1990; 323:56–565.
203. Trent JM, Meysken FL, Salmon SE, et al. Relation of cytogenetic abnormalities and clinical outcome in metastatic melanoma. N Engl J Med. 1990; 322:1508–1511.
204. Turleau C, De Grouchy J. Constitutional karyotypes in retinoblastoma. Ophth Paediatr Genet. 1987; 8:11–17.
205. Cowell JK, Hungerford J, Rutland P, Jay M. Genetic and cytogenetic analysis of patients showing reduced esterase-D levels and mental retardation from a survey of 500 individuals with retinoblastoma. Ophth Paediatr Genet. 1989; 10:117–127.
206. Balaban G, Gilbert F, Nichols W, et al. Abnormalities of chromosome 13 in retinoblastomas from individuals with normal constitutive karyotypes. Cancer Genet Cytogenet. 1982; 6:213–221.
207. Knudson AG. A statistical study of retinoblastoma. Proc Natl Acad Sci USA. 1971; 68:820–825.
208. Friend SH, Bernards R, Rogel S, et al. A human DNA segment with properties of the gene that predisposes to retinoblastoma and osteosarcoma. Nature. 1986; 323:643–646.
209. Wagner S, Green MR. Retinoblastoma: A transcriptional tryst. Nature. 1991; 352:189–190.
210. Kitchin FD, Ellsworth RM. Pleiotropic effects of the gene for retinoblastoma. J Med Genet. 1974; 11:244–246.
211. Cance WG, Brennan MF, Dudas ME, et al. Altered expression of the retinblastoma gene product in human sarcomas. N Engl J Med. 1990; 323:1457–1462.
212. Wunder JS, Czitrom AA, Kandel R, Andrulis IL. Analysis of alterations in the retinoblastoma gene and tumor grade in bone and soft tissue sarcomas. J Natl Cancer Inst. 1991; 83:194–200.
213. Ginsberg AM, Raffeld M, Cossman J. Inactivation of the retinoblastoma gene in human lymphoid neoplasms. Blood. 1991; 77:833-840.
214. Lee WH. The molecular basis of cancer suppression by the retinoblastoma gene. Int Symp Princess Takamatsu Cancer Res Fund. 1989; 20:159–170.
215. Dyson N, Howley PM, Munger K, Harlow E. The human papilloma virus-16 E7 oncoprotein is able to bind to the retinoblastoma gene product. Science. 1989; 243:934–937.
216. Wiggs J, Nordenskjold M, Yandell D, et al. Prediction of the risk of hereditary retinoblastoma, using DNA polymorphisms within the retinoblastoma gene. N Engl J Med. 1990; 318:151–157.
217. Orita M, Iwahana H, Kanazawa H, et al. Detection of polymorphisms of human DNA by gel electrophoresis as single-strand conformation polymorphisms. Proc Natl Acad Sci USA. 1989; 86:2766–2770.
218. Fountain JW, Wallace MR, Bruce MA, et al. Physical mapping of a translocation breakpoint in neurofibromatosis. Science. 1989; 244:1085–1087.
219. Xu G, O'Connell P, Viskochil D, et al. The neurofibromatosis type 1 gene encodes a protein related to GAP. Cell. 1990; 62:599–608.
220. Malkin D, Li FP, Strong LC, et al. Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms. Science. 1990; 250:1233–1238.
221. Li FP, Fraumeni JFJ. Soft-tissue sarcomas, breast cancer, and other neoplasms. A familial syndrome? Ann Int Med. 1969; 71:747–752.
222. Williams WR, Strong LC. Genetic epidemiology of soft tissue sarcomas in children. In: Muller and Weber, eds. Familial Cancer—First International Research Conference. Basel, Switzerland: Karger, 1985: 151–153.
223. Levine AJ, Momand J, Finlay CA. The p53 tumour suppressor gene. Nature. 1991; 351:453–456.
224. Scheffner M, Werness BA, Huibregtse JM, et al. The E6 oncoprotein encoded by human papillornavirus types 16 and 18 promotes the degradation of p53. Cell. 1990; 63:1129–1136.
225. Mikkelsen T, Cavenee WK. Suppressors of the malignant phenotype. Cell Growth Diff. 1990; 1:201–207.
226. Ponder B. Gene losses in human tumors. Nature. 1988; 335:400–402.
227. Fearon ER, Vogelstein B. A genetic model for colorectal tumorigenesis. Cell. 1990; 61:759–767.
228. Baker SJ, Fearon, ER, Nigro JM, et al. Chromosome 17 deletions and p53 gene mutations in colorectal. carcinomas. Science. 1989; 244:217–221.
229. Fearon ER, Cho KR, Nigro JM, et al. Identification of a chromosome 18q gene that is altered in colorectal cancers. Science. 1990; 247:49–56.
230. Kinzler KW, Nilbert MC, Vogelstein B, et al. Identification of a chromosome 5q21 gene that is mutated in colorectal cancers. Science. 1991; 251:1366–1370.
231. Kinzler KW, Nilbert MC, Su L-K, et al. Identification of FAP locus genes from chromosome 5q21. Science. 1991; 253:661–665.
232. Nishisho I, Nakamura Y, Miyoshi Y, et al. Mutations of chromosome 5q21 genes in FAP and colorectal cancer patients. Science. 1991; 253:665–669.
233. Vogelstein B, Fearon ER, Kern SE, et al. Allelotype of colorectal carcinomas. Science. 1989; 244:207–211.
234. Kern SE, Fearon ER, Kasper WFT, et al. Clinical and pathological associations with allelic loss in colorectal carcinoma. JAMA. 1989; 261:3099–3103.
235. Sidransky D, von Eschenbach A, Tsai YC, et al. Identification of p53 gene mutations in bladder cancers and urine samples. Science. 1991; 252:706–709.
236. Meling GI, Rognum TO, Clausen OP, et al. Association between DNA ploidy pattern and cellular atypia in colorectal cancers. A new clinical application of DNA flow cytometric study? Cancer. 1991; 67:1642–1649.
237. Giaretti W, Danova M, Geido E, et al. Flow cytometric DNA index in the prognosis of colorectal carcinoma. Cancer. 1991; 67:1921–1927.
238. Hood DL, Petras RE, Edinger M, et al. DNA ploidy and cell cycle analysis of colorectal carcinoma by flow cytometry. A prospective study of 137 cases using fresh whole cell suspensions. Am J Clin Path. 1990; 93:615–620.
239. James CD, Carlbom E, Dumanski JP, et al. Clonal genomic alterations in glioma malignancy stages. Cancer Res. 1988; 48:5546–5551.
240. Scrable H, Sapienza C, Cavenee WK. Genetic and epigenetic losses of heterozygosity in cancer predisposition and progression. Adv Cancer Res. 1990; 54:25–62.
241. Olapade IO, Pomykala H, Bohlander S, et al. Mapping of the minimum region of deletions of the short arm of chromosome 9 associated with human neoplasia. Submitted for publication.
242. Bressac B, Kew M, Wands J, Ozturk M. Selective G to T mutations of p53 gene in hepatocellular carcinoma from southern Africa. Nature. 1991; 350:429–431.
243. Hsu IC, Metcalf RA, Sun T et al. Mutational hotspot in the p53 gene in human hepatocellular carcinomas. Nature. 1991; 350:427–428.
244. Henle W, Henle G. The Epstein-Barr virus in Burkitt's lymphoma and nasopharyngeal carcinoma. Ann Clin Lab Sci. 1974; 4:109–114.
245. Nonoyama N, Huang CH, Papano JS, et al. DNA of Epstein-Barr virus detected in tissue of Burkitt's lymphoma and nasopharyngeal carcinoma. Proc Natl Acad Sci. 1973; 70:3265–3268.
246. Hanto DW, Frizzera G, Flurtilo DT, et al. Clinical spectrum of lymphoproliferative disorders in renal transplant recipients and evidence for the role of Epstein-Barr virus. Cancer Res. 1981; 41:4253–4261.
247. Hanto DW, Sakamoto K, Purtilo DT, et al. The Epstein-Barr virus in the pathogenesis of post-transplant lymphoproliferative disorders. Surgery. 1981; 90:204–213.
248. Hamilton-Dutoit SJ, Pallesen G, Franzman MB, et al. AIDS related lymphoma. Histophathology, immunophenotype and association with Epstein-Barr virus as demonstrated by in situ hybridization. Am J Pathol. 1991; 138:149–163
249. Shearer WT, Ritz J, Finegold MJ, et al. Epstein-Barr virus-associated B-cell proliferations of diverse clonal origins after bone marrow transplantation in a 12-year-old patient with severe combined immunodeficiency. N Engl J Med. 1985; 312:1151–1159.
250. Leyrraz S, Henle W, Clahinian AP, et al. Association of Epstein-Barr virus with thymic carcinoma. N Engl J Med. 1985; 312:1296–1299.
251. Weiss LM, Movahed LA, Warnke RA, Sklar J. Detection of Epstein-Barr virus genomes in Reed-Sternberg cells of Hodgkin's disease. N Engl J Med. 1989; 320:502–506.
252. Henderson S, Rowe M, Gregory C, et al. Induction of bcl-2 expression by Epstein-Barr virus latent membrane protein 1 Protects infected B cells from programmed cell death. Cell. 1991; 65:1107–1115.
253. Reitz MSJ, Kalyanarraman VS, Robert-Gurnoff M, et al. Human T cell leukemia lymphoma virus: the retrovirus of adult T cell leukemia/lymphoma. J Inf Dis. 1983; 147:399–405.
254. Blattner WA, Blayney DW, Jaffe ES, et al. Epidemiology of HTLV-associated leukemia. Hematol Bluttransfus. 1983; 28:148–155.
255. Grassman R, Dengler C, Muller-Fleckenstein I, et al. Transformation to continuous growth of primary human T lymphocytes by human T-cell leukemia virus type I X-region genes transduced by a Herpesvirus saimiri vector. Proc Natl Acad Sci USA. 1989; 86:3351–3355.
256. Tanaka A, Takahashi C, Yamaoka S, et al. Oncogenic transformation by the tax gene of human T-cell leukemia virus type I in vitro. Proc Natl Acad Sci USA. 1990; 87:1071–1075.
257. Greene W, Leonard W, Wano W, et al. Trans-activator gene of HTLV-II induces IL-2 receptor and IL-2 cellular gene expression. Science. 1986; 232:877–880.
258. Boshart M, Gissman L, Ikenberg H, et al. A new type of human papilloma virus, Its presence in genital cancer biopsies and in cell lines derived from cervical cancer. EMBO J. 1984; 3:1151–1157.
259. Dyson N, Howley PM, Munger K, Harlow E. The human papilloma virus-16 E7 oncoprotein is able to bind to the retinoblastoma gene product. Science. 1989; 243.934–937.
260. Munger K, Werness BA, Dyson N, et al. Complex formation of human papillornavirus E7 proteins with the retinoblastoma tumor suppressor gene product. EMBO J. 1989; 8:4099–4105.
261. Werness BA, Levine AJ, Howley PM. Association of human papillomavirus types 16 and 18 E6 proteins with p53. Science. 1990; 248:76–79.
262. Fourel G, Trepo C, Bougueleret L, et al. Frequent activation of n-myc genes by hepadnavirus insertion in woodchuck liver tumors. Nature 1990; 347:294–298.
263. Paronetto F, Tennant BC. Woodchuck hepatitis virus infection: a model of human hepatic diseases and hepatocellular carcinoma. Prog Liv Dis. 1990; 9:463–483.
264. Kim CM, Koike K, Saito I, Miyamura T, Jay G. Hbx gene of hepatitis B virus induces liver cancer in transgenic mice. Nature. 1991; 351:317–320.
265. Seto E, Mitchell PJ, Yen TSB. Transactivation by the hepatitis B virus X protein depends on AP-2 and other transcription factors. Nature. 1990; 344:72–74.